Clearside Biomedical (NSDQ:CLSD) touted new analyses of data from the company’s Phase III pivotal trial of suprachoroidal CLS-TA in people with uveitic macular edema.
The company’s investigational treatment is a suspension of triamcinolone acetonide formulated to be delivered to the back of the eye via the suprachoroidal space.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical reports analyses from pivotal trial of eye drug appeared first on MassDevice.
from MassDevice https://ift.tt/2DaQC8M
Cap comentari:
Publica un comentari a l'entrada